drugset / Trial / NCT00262041

Study of the Safety and Immune Response of a Meningococcal Conjugate Vaccine Administered to Healthy Adolescents

NCT00262041

Phase 2 Completed 524 enrolled Novartis Vaccines Novartis · collab
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to evaluate the safety and immunogenicity of Novartis Meningococcal ACWY Conjugate Vaccine in comparison to licensed meningococcal polysaccharide vaccine administered to healthy adolescents ages 11 to 17 years.

Timeline

Start
2004-10
Primary completion
2006-03
Completion
2006-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator MenACWY polysaccharide vaccine Vaccine
Subject Menveo Vaccine

Indications